-
公开(公告)号：US11274147B2
公开(公告)日：2022-03-15
申请号：US16965565
申请日：2019-01-31
发明人： Constantin Adrian Apetri , Jaroslaw Juraszek , Roosmarijn Janson , Harmke Cornelia Verveen , Bunga Berdien Siregar
摘要： The invention relates to binding molecules and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The invention also relates to diagnostic, prophylactic and therapeutic methods using the binding molecules or antigen-binding fragments.
-
公开(公告)号：US11235051B2
公开(公告)日：2022-02-01
申请号：US16634205
申请日：2018-07-27
发明人： Ronald Vogels , Marijn Van Der Neut Kolfschoten , Darrell J. Irvine , Ron Weiss , Ely Blanton Porter , Mariane Bandeira Melo , Tasuku Kitada
IPC分类号： A61K48/00 , A61K9/127 , C07K14/535 , C12N15/85 , A61K31/7115 , A61K39/12 , C12N15/86 , A61K39/00
摘要： Compositions and methods are described for inducing an immune response against an immunogen in humans. The induced immune response is obtained by administering a heterologous prime-boost combination of an in vitro transcribed (IVT) self-replicating RNA (repRNA) and an adenovirus vector. The compositions and methods can be used to provide a protective immunity against a disease, such as a viral infection or a cancer, in humans.
-
公开(公告)号：US11229692B2
公开(公告)日：2022-01-25
申请号：US16613206
申请日：2018-05-15
IPC分类号： A61K39/12 , A61P31/14 , A61K35/761 , C12N15/86 , A61K39/00
摘要： Compositions, vaccines and methods using adenovirus vectors for inducing protective immunity against a respiratory syncytial virus (RSV) infection are described.
-
公开(公告)号：US20210205440A1
公开(公告)日：2021-07-08
申请号：US17249372
申请日：2021-03-01
IPC分类号： A61K39/155 , C07K14/135 , C12N7/00
摘要： Stable pre-fusion respiratory syncytial virus (RSV) F proteins, immunogenic compositions including the proteins and uses thereof for the prevention and/or treatment of RSV infection are described.
-
公开(公告)号：US11052147B2
公开(公告)日：2021-07-06
申请号：US16612561
申请日：2018-05-15
IPC分类号： A61K39/00 , A61K39/12 , C12N15/86 , C12N7/00 , A61K39/275 , A61K39/285 , A61P31/04 , A61K47/20
摘要： Described herein are compositions and pharmaceutical compositions including poxviruses, in particular vaccinia virus such as modified vaccinia Ankara (MVA) virus, a sulfate salt at a concentration between about 5 mM and 300 mM and a buffer, wherein the composition has a pH of between about 6.0 and 8.5. Also described are methods for stabilizing a poxvirus composition by preparing said viral formulation.
-
公开(公告)号：US20210138060A1
公开(公告)日：2021-05-13
申请号：US17091296
申请日：2020-11-06
发明人： Christopher RODE , Brian POLILLI , John SCHREFFLER
摘要： Described herein is a process for protein purification, particularly a process for the purification of a glycoprotein, such as an HIV envelope protein, useful for vaccines or biotherapeutics.
-
公开(公告)号：US11001858B2
公开(公告)日：2021-05-11
申请号：US16310701
申请日：2017-06-19
发明人： Kerstin Wunderlich , Jort Vellinga
摘要： The invention provides a bidirectional hCMV-rhCMV promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-rhCMV promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
-
公开(公告)号：US10953087B2
公开(公告)日：2021-03-23
申请号：US16305169
申请日：2017-05-29
IPC分类号： A61K39/00 , C07K14/005 , A61K39/155 , C07K16/10 , C12N7/00 , C07K14/135
摘要： Stable pre-fusion respiratory syncitial virus (RSV) F proteins, immunogenic compositions including the proteins and uses thereof for the prevention and/or treatment of RSV infection are described.
-
公开(公告)号：US20200299364A1
公开(公告)日：2020-09-24
申请号：US16946092
申请日：2020-06-05
IPC分类号： C07K16/10 , C07K16/08 , G01N33/569
摘要： Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.
-
公开(公告)号：US20200230225A1
公开(公告)日：2020-07-23
申请号：US16634205
申请日：2018-07-27
发明人： Ronald VOGELS , Marijn VAN DER NEUT KOLFSCHOTEN , Darrell J. IRVINE , Ron WEISS , Ely Blanton PORTER , Mariane Bandeira MELO , Tasuku KITADA
摘要： Compositions and methods are described for inducing an immune response against an immunogen in humans. The induced immune response is obtained by administering a heterologous prime-boost combination of an in vitro transcribed (IVT) self-replicating RNA (repRNA) and an adenovirus vector. The compositions and methods can be used to provide a protective immunity against a disease, such as a viral infection or a cancer, in humans.
-
-
-
-
-
-
-
-
-
搜索结果
217 条记录 (耗时 0.029 秒)
